Skip Nav Destination
Close Modal
Update search
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Article Type
Date
Availability
1-3 of 3
Keywords: sorafenib
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Articles
Jan Peveling-Oberhag, Claudia Döring, Sylvia Hartmann, Natalie Filmann, Angelika Mertens, Albrecht Piiper, Eva Herrmann, Martin-Leo Hansmann, Stefan Zeuzem, Jörg Trojan, Martin-Walter Welker
Journal:
Clinical Science
Clin Sci (Lond) (2015) 128 (1): 29–37.
Published: 27 August 2014
...Jan Peveling-Oberhag; Claudia Döring; Sylvia Hartmann; Natalie Filmann; Angelika Mertens; Albrecht Piiper; Eva Herrmann; Martin-Leo Hansmann; Stefan Zeuzem; Jörg Trojan; Martin-Walter Welker Sorafenib is the standard treatment for patients with advanced hepatocellular carcinoma (HCC). However...
Includes: Supplementary data
Articles
Caroline Erös de Bethlenfalva-Hora, Joachim C. Mertens, Anne-Christine Piguet, Joachim Kettenbach, Johannes Schmitt, Luigi Terracciano, Rosemarie Weimann, Jean-François Dufour, Andreas Geier
Journal:
Clinical Science
Clin Sci (Lond) (2014) 126 (3): 243–252.
Published: 09 October 2013
... inhibitor sorafenib prolongs survival in advanced HCC. We examined the effects of RFA alone and in combination with sorafenib on a bystanding tumour in a two-tumour rat model of HCC. A total of 80 rats were implanted with two liver tumours and randomized to four treatment groups: vehicle and sham operation...
Includes: Supplementary data
Articles
Ching-Chih Chang, Chiao-Lin Chuang, Fa-Yauh Lee, Sun-Sang Wang, Han-Chieh Lin, Hui-Chun Huang, Tzu-Hua Teng, Shao-Jung Hsu, Hsian-Guey Hsieh, Shou-Dong Lee
Journal:
Clinical Science
Clin Sci (Lond) (2013) 124 (7): 457–466.
Published: 07 December 2012
... abnormal pulmonary vasodilatation and/or angiogenesis. In the present study, we evaluated anti-angiogenesis therapy using sorafenib in experimental HPS animals. HPS was induced by CBDL (common bile duct ligation) in rats. A 2-week 10 mg·(kg of body weight) −1 ·day −1 treatment regimen of sorafenib...
